To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
TRPML1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TRPML1, including- -F408* (heterozygous and homozygous) - in development, est late 2026
- -DOX-NGN2 + TMEM192-HA + Knockout (heterozygous and homozygous) - in development, est late 2026
SNCA Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SNCA, including- -A30P (heterozygous and homozygous)
- -A53T (heterozygous and homozygous)
- -E46K (heterozygous and homozygous)
- -DOX-NGN2 + TMEM192-HA + A53T (heterozygous and homozygous) - in development, est late 2026
ATP13A2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in ATP13A2, including:- -T517I (heterozygous and homozygous)
- -R745H (heterozygous and homozygous) - in development, est late 2026
- -M854R (heterozygous and homozygous)
- -c1306 (heterozygous and homozygous)
- -DOX-NGN2 + TMEM192-HA + c1306 (heterozygous and homozygous) - in development, est late 2026
USP30 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered heterozygous and homozygous of USP30.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD).This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Estimated availability: late 2026
TRPM2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CLN3, including - rs56379273 (heterozygous and homozygous) - in development, est late 2026
- Knockout (homozygous) - in development, est late 2026
VPS13C Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in VPS13C, including - -R117* (heterozygous and homozygous) - in development, est late 2025
- -G1389R (heterozygous and homozygous) - in development, est late 2025
- -Knockout (homozygous) - in development, est late 2025
SMPD1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SMPD1, including - -Q294K (heterozygous and homozygous) - in development, est late 2025
- -L262Rfs*s (heterozygous and homozygous) - in development, est late 2025
- -Knockout (homozygous) - in development, est late 2025
SMPD1 Antibody
Antibody
Rabbit monoclonal antibody directed against human SMPD1. Developed for use in immunoblotting, immunocytochemistry, and immunoprecipitation applications. This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Anticipated Availability: Q4 2027
LRRK2 KO MEF
Immortalized Cell
Mouse embryonic fibroblast line with knockout of LRRK2. This cell line development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Anticipated availability: Late 2025
OMP25 Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse OMP25 for immunoprecipitation of endogenous mitochondria.This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Mid 2026
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic